Last Updated: June 25, 2026

Patent: 10,376,652


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,376,652
Title:Automatic injection device with a top release mechanism
Abstract:The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
Inventor(s):Markussen Tom Hede
Assignee:Novo Nordisk A/S
Application Number:US15441638
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,376,652
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 10,376,652: What the Claims Cover and How the US Landscape Actually Positions Them

No analysis can be produced because the claims text for US 10,376,652 is missing. Without the claim set, it is not possible to map claim scope to prior art, identify claim dependencies, evaluate novelty/obviousness risk, or characterize the design-around space across US filings and litigated families.

What are the claim elements you are analyzing?

No claim text was provided after “The claims are:” so the claim-by-claim construction, scope, and infringement/validity positioning cannot be performed.

What does the patent landscape show for validity and freedom-to-operate?

The necessary claim details are absent. Landscape assessment requires at minimum:

  • independent claim subject matter and key limitations
  • dependent claim add-ons that narrow scope
  • priority date(s), filing history, and maintenance status
  • the exact wording of terms that drive claim construction

Can the patent be positioned against the most relevant prior art?

Not with the claim set absent. Prior-art mapping must be anchored to specific limitations (e.g., “a polymer with X,” “wherein Y is substituted,” “configured to perform Z”), and those limitations are unknown.


Key Takeaways

  • US patent landscape and claims-critical analysis cannot be generated because the claim text for US 10,376,652 is not included.
  • Claim-by-claim validity risk and design-around mapping depend on exact claim language, which is unavailable in the provided input.

FAQs

  1. Can you analyze US 10,376,652 without the claim text?
    No. Scope, novelty, obviousness, and design-around analysis require the exact claim language.

  2. What is required to do a claim-level patentability and infringement landscape review?
    The full claim set (all independent and dependent claims) plus any prosecution-relevant context.

  3. Why does missing claim language block a prior-art mapping?
    Prior-art mapping must test each claim limitation; without wording, the match cannot be performed.

  4. What parts of the claim set drive validity and FTO outcomes?
    Independent claim limitations and the narrowing dependent limitations.

  5. Will this analysis cover design-arounds and litigation signals?
    Only once claim scope is known, because design-arounds must target specific claim elements.


References

[1] No sources were cited because US 10,376,652 claims were not provided in the prompt.

More… ↓

⤷  Start Trial

Details for Patent 10,376,652

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 June 16, 2005 ⤷  Start Trial 2037-02-24
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 October 31, 2013 ⤷  Start Trial 2037-02-24
Novo Nordisk Inc. NOVOLOG MIX 50/50 insulin aspart protamine and insulin aspart Injectable Suspension 021810 August 26, 2008 ⤷  Start Trial 2037-02-24
Seqirus Inc. FLUAD influenza vaccine, adjuvanted Injection 125510 November 24, 2015 ⤷  Start Trial 2037-02-24
Seqirus Inc. FLUAD,FLUAD QUADRIVALENT influenza vaccine, adjuvanted Injection 125510 February 21, 2020 ⤷  Start Trial 2037-02-24
Novo Nordisk Inc. TRESIBA insulin degludec Injection 203314 September 25, 2015 ⤷  Start Trial 2037-02-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.